TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10791645
Drug: Bioabsorbable poly‐L‐lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable poly‐L‐lactide lag screws (3 screws of 6.3 mm diameter)
Study: 10791645
Drug: Bioabsorbable poly‐L‐lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable poly‐L‐lactide lag screws
Study: 3730021
Drug: Flupenthixol (Fluanxol)
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (Fluanxol) 0.5 mg, 1 mg, and 2 mg/day
Study: 28970207
Drug: Hydroxychloroquine 400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg/day and sulfasalazine 2000 mg/day (arm 1)
Study: 28970207
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus adalimumab 40 mg/2 weeks (arm 2)
Study: 24767603
Drug: Low-intensity online
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity online CBT-based treatment consisting of six weekly modules; participants receive weekly post-session feedback.
Study: 20339354
Drug: Hourly mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly mean method
Study: 18823460
Drug: Pre-operative i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative i.v. fluid loading with a balanced crystalloid solution (1 ml/kg/h over 48 h)
Study: 27256706
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hUCB-MSCs (5.0 × 10^7)
Study: 27256706
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hUCB-MSCs (2.5 × 10^7)
Study: 23179858
Drug: Glibenclamide (Gb)
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide (Gb) 3.5 mg, intravenously or orally
Study: 23179858
Drug: Metabolite M1
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolite M1 3.5 mg, intravenously
Study: 23179858
Drug: Metabolite M2
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolite M2 3.5 mg, intravenously
Study: 21654053
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d for six months
Study: 21654053
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lower doses of statins)
Study: 19505424
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA) infusion (30 g daily for 3 days)
Study: 23724353
Drug: Duloxetine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (any dose)
Study: 8486876
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 20% Lipofundin MCT/LCT (1/1) per day
Study: 8486876
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 20% Lipofundin S (LCT) infused over 8 h each evening
Study: 3497041
Drug: Troleandomycin 2
Normalized name: troleandomycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troleandomycin 2 g/day p.o. for 7 days
Study: 19884374
Drug: Nemonoxacin (TG-873870)
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (TG-873870) 75 to 1,000 mg once daily for 10 days
Study: 19884374
Drug: Nemonoxacin (TG-873870)
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (TG-873870) 500 mg cohort
Study: 16870075
Drug: P‐ERMS (KADIAN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐ERMS (KADIAN) once‐daily (QD) dosing
Study: 16870075
Drug: CRO (OxyContin)
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CRO (OxyContin) twice‐daily (BID) dosing
Study: 12965981
Drug: 2.5‐mg dronabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5‐mg dronabinol (delta‐9‐tetrahydrocannabinol) capsule
Study: 11789210
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SM) with oxygen inhalation and anti-infection agents (SM 40 ml + 10% glucose 100 ml)
Study: 11789210
Drug: Aminophylline (AP)
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (AP) with 10% glucose (AP 0.25 g plus 10% glucose 100 ml)
Study: 8874180
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HDAC) at 2 g/m2 intravenously every 12 hours for 12 doses plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Study: 8874180
Drug: Standard-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose cytarabine (SDAC) 200 mg/m2/d for 7 days by continuous infusion plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Study: 1997047
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and Thiopentone (combination)
Study: 6647201
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of lipophilic beta-blockers
Study: 29898842
Drug: ARNI prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARNI prescription post-guideline publication
Study: 29898842
Drug: ARNI prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARNI prescription pre-guideline publication
Study: 25062420
Drug: Lifestyle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle + Drug
Study: 19961574
Drug: Sodium ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ibuprofen (2x256 mg tablets)
Study: 19961574
Drug: Ibuprofen/poloxamer (2x200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/poloxamer (2x200 mg tablets + 60 mg poloxamer 407)
Study: 19961574
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen (2x200 mg tablets)
Study: 9549651
Drug: Felbamate (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate (3,000 or 3,600 mg/day)
Study: 9549651
Drug: Felbamate (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate (3,000 or 3,600 mg/day) with erythromycin (333 mg three times daily for 10 days)
Study: 23652752
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate 0.4% ointment
Study: 23652752
Drug: Lidocaine chlorohydrate
Normalized name: Aluminum Chlorohydrate
DrugBank: Aluminum chlorohydrate (DB11573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine chlorohydrate 2.5% gel
Study: 8889855
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (greater than 1000 mg/day) with physical activity
Study: 8889855
Drug: Mean calcium
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean calcium intake less than 1000 mg/day with physical activity
Study: 9141257
Drug: Ibuprofen 8
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 8 mg/kg
Study: 3882308
Drug: Ibuprofen 12
Normalized name: ibuprofen 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 12 mg/kg
Study: 3882308
Drug: Ibuprofen 14
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 14 mg/kg
Study: 3882308
Drug: Ibuprofen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (all doses except 0 mg/kg)
Study: 30740297
Drug: Denosumab (DB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15; n=125)
Study: 30740297
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA group; 4 mg per 4 weeks; n=125)
Study: 20236990
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) delivered by trained nurses in three individual appointments
Study: 19388288
Drug: Antibiotic-impregnated ventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-impregnated ventricular catheter (Group A)
Study: 19388288
Drug: Plain ventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ventricular catheters with prophylactic dual antibiotics (Group B)
Study: 9440384
Drug: Traditional yogurt
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional yogurt (125 g/d for 1 month)
Study: 9440384
Drug: Milk fermented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fermented with yogurt cultures and Lactobacillus casei (YC) (125 g/d for 1 month)
Study: 9440384
Drug: Nonfermented gelled
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfermented gelled milk (125 g/d for 1 month)
Study: 7602342
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 (arm A)
Study: 7602342
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m2 plus doxorubicin 50 mg/m2 (arm C)
Study: 345561
Drug: Steroids (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (control group)
Study: 25751578
Drug: Losmapimod, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod, 7.5 mg bid orally
Study: 17452162
Drug: Amiodarone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (n = 696) at doses >2.0 mg/kg
Study: 17452162
Drug: Amiodarone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (n = 559) at doses >3.0 mg/kg
Study: 17452162
Drug: Amiodarone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (n = 219) at doses >4.0 mg/kg
Study: 17452162
Drug: Amiodarone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (n = 837) with a mean daily dose of 3.7 mg/kg (300 mg)
Study: 14620524
Drug: New paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: New paracetamol formulation with sodium bicarbonate
Study: 14620524
Drug: Conventional paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracetamol formulation
Study: 10632650
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy (two single triple capsules containing 60 mg of bismuth subcitrate, 125 mg of tetracycline, and 125 mg of metronidazole) plus lansoprazole 30 mg b.d. for 7 days
Study: 8938547
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (single subcutaneous dose)
Study: 3868934
Drug: 4'-epi-adriamycin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4'-epi-adriamycin (EPI) 50 mg/day for 6 days (regimen A)
Study: 3868934
Drug: 4'-epi-adriamycin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4'-epi-adriamycin (EPI) 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B)
Study: 20591171
Drug: Telerehabilitation (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (TR) intervention using a combination of three videotaped visits and five telephone calls, an in-home messaging device, and additional telephonic contact as needed over a 3-month study period
Study: 10337455
Drug: Myrtol standardized
Normalized name: myrtol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtol standardized (MYS, Gelomyrtol forte, 3 x 300 mg)
Study: 1819779
Drug: Intramuscular beta-interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular beta-interferon (3 x 10(6) IU for 10 consecutive days)
Study: 1819779
Drug: Placebo intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intramuscular injections
Study: 7146040
Drug: Controlled-release preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus)
Study: 17470864
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg IV every 2 weeks and erlotinib 150 mg orally daily
Study: 15370671
Drug: Early discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early discontinuation of antibiotic therapy in FUO patients
Study: 3221960
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks
Study: 3221960
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks + CCNU in one dose of 100 mg/m repeated at intervals of 6‐8 weeks
Study: 24565129
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (Group IVM)
Study: 24565129
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (Group EM)
Study: 24565129
Drug: Epidural morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine-bupivacaine (Group EMB)
Study: 24565129
Drug: Epidural morphine-ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine-ropivacaine (Group EMR)
Study: 9624783
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 500 mg once daily for 7 days
Study: 9624783
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 500 mg twice daily for 10 days
Study: 7837834
Drug: Zemide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zemide 20 (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Study: 7837834
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available tablet formulation (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Study: 26814847
Drug: TwHF based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF based therapy in predictor positive (P+) group
Study: 26814847
Drug: TwHF based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF based therapy in predictor negative (P-) group
Study: 26814847
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Sulfasalazine combination therapy (M) in predictor positive (P+) group
Study: 26814847
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Sulfasalazine combination therapy (M) in predictor negative (P-) group
Study: 16978844
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus probiotic food (250 mL of yogurt containing Bifidobacterium animalis and Lactobacillus casei at 10^7 CFU/mL) for 1 week and administered for 3 months
Study: 15343566
Drug: Balloon angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon angioplasty plus cilostazol (200 mg/day for 6 months)
Study: 10937764
Drug: Iohexol (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (350 mg I/ml)
Study: 26314432
Drug: Arsenous acid
Normalized name: Arsenous acid
DrugBank: Arsenous acid (DB04456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arsenous acid (H3AsO3) treatment
Study: 21391828
Drug: Peer health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer health workers (PHWs) providing care; specific dosage and duration not mentioned.
Study: 12912807
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins C (500 mg/d) and E (400 IU/d) for 6 weeks
Study: 1997932
Drug: MTC +
Normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTC + L (metoclopramide 1 mg/kg or 0.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Study: 1997932
Drug: ALZ +
Normalized name: Alzheimer's Disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ + L (alizapride 3 mg/kg or 1.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Study: 1997932
Drug: MTC +
Normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTC + L
Study: 1997932
Drug: ALZ +
Normalized name: Alzheimer's Disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ + L
Study: 31404221
Drug: Open abdomen
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open abdomen management with negative-peritoneal-pressure therapy (NPPT)
Study: 30153752
Drug: Ketamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine plus placebo (0.5 mg/kg of ketamine)
Study: 30153752
Drug: Ketamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine plus naltrexone (50 mg of naltrexone preceding ketamine)
Study: 23158714
Drug: Univent blocker
Normalized name: verapamil hydrochloride Extended Release Oral Capsule [Univer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Univent blocker (UNI)
Study: 23158714
Drug: Coopdech bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coopdech bronchial blocker (BB)
Study: 15353973
Drug: Low-dose Vacc-4x
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Vacc-4x
Study: 15353973
Drug: High-dose Vacc-4x
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Vacc-4x
Study: 27940188
Drug: Opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid agonist treatment-as-usual
Study: 25370889
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg daily for 56 days
Study: 25370889
Drug: Placebo (days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (days 1-28) followed by Armodafinil 150 mg daily (days 29-56)
Study: 22462234
Drug: Guo's Ma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guo's Ma Qian Decoction, initial dose 0.4 g, increased by 0.05 g every two days, max 1.2 g/day.
Study: 16446336
Drug: CVI fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CVI fluorouracil (FU) 225 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid (arm 1)
Study: 16446336
Drug: CVI FU
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI FU 225 mg/m2 per day Monday to Friday, 120 hours per week plus irinotecan 50 mg/m2 once weekly for 4 weeks plus pelvic radiation therapy 50.4 to 54 Gy at 1.8 Gy per day (arm 2)
Study: 12844212
Drug: Exercise (supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (supervised aerobic, weight‐bearing and weight‐lifting exercise, three times per week) with calcium supplementation (800 mg daily)
Study: 8996468
Drug: Tenidap (40-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap (40-200 mg/day)
Study: 1282537
Drug: Warfarin (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (traditional and low-dose regimens)
Study: 1282537
Drug: Aspirin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (three groups)
Study: 31034598
Drug: ontuxizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ontuxizumab (8 mg/kg) plus gemcitabine and docetaxel (G/D)
Study: 31034598
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus gemcitabine and docetaxel (G/D)
Study: 24947675
Drug: Oxycodone orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone orodispersible tablet (OOT) 20 mg
Study: 24947675
Drug: Paracetamol orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol orodispersible tablet (POT) 500 mg
Study: 23375525
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d of ω‐3 PUFA
Study: 23375525
Drug: 3.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g/d of ω‐3 PUFA
Study: 21410828
Drug: Conjugated Estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Estrogen (CEE) 0.625 mg/day
Study: 21410828
Drug: Conjugated Estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Estrogen (CEE) 0.625 mg/day plus Medroxyprogesterone Acetate (MPA) 2.5 mg/day
Study: 19270449
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg intravenous mesna administered predialysis for 1 week
Study: 19270449
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered predialysis for 1 week
Study: 19270449
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg intravenous mesna administered predialysis for 4 weeks
Study: 19270449
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered predialysis for 4 weeks
Study: 15254053
Drug: Arm 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Cisplatin 10 mg/m² daily and fluorouracil (FU) 400 mg/m² continuous infusion (CI) daily for the final 10 days of treatment
Study: 15254053
Drug: Arm 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2: Hydroxyurea 1 g every 12 hours and FU 800 mg/m²/d CI delivered with each fraction of radiation
Study: 15254053
Drug: Arm 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3: Weekly paclitaxel 30 mg/m² and cisplatin 20 mg/m²
Study: 12027068
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA (180 microg ex-actuator)
Study: 12027068
Drug: Albuterol CFC
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol CFC (180 microg ex-actuator)